Recruiting

Observational Study

Sponsor:

Northwestern University

Code:

NCT05111223

Conditions

Healthy

Eligibility Criteria

Sex: All

Age: 18 - 40

Healthy Volunteers: Accepted

Interventions

Real transcranial magnetic stimulation (TMS) before conditioning

Real transcranial magnetic stimulation (TMS) before devaluation test

Sham transcranial magnetic stimulation (TMS)

Study Details

Brief summary:

This research study examines the contribution of orbitofrontal cortex (OFC) networks to decision-making.

Conditions

Healthy

Study ID

NCT05111223

Start date

Jul 12, 2022

Status verified date

Aug, 2024

Completion date

Aug 31, 2026

Anticipated

Primary completion date

Aug 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 40

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age between 18 and 40 years old
  • Right-handed
  • Fluent English speakers

Exclusion Criteria:

  • History of significant neurological conditions (e.g., epilepsy, dementia, multiple sclerosis, brain tumors, etc.)
  • History of major psychiatric conditions (e.g., general anxiety disorder, depression, schizophrenia, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, substance use disorder, etc.)
  • Significant medical illnesses (e.g., cancer, meningitis, chronic obstructive pulmonary disease, cardiovascular disease, etc.)
  • Significant cerebrovascular risk factors (e.g., hypertension, diabetes, elevated cholesterol, etc.)
  • Current use of psychoactive medications (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, citalopram, escitalopram, fluoxetine, diazepam, etc.)
  • Smell or taste dysfunction
  • History of significant allergies requiring hospitalization for treatment
  • History of severe asthma requiring hospitalization for treatment
  • Habitual smoking
  • History of eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge-eating disorder, etc.)
  • Dieting or fasting
  • Magnetic implants (e.g., shunts or stents, aneurysm clips, surgical clips, cochlear implants, metal bone/joint pins, plates and screws, eyelid spring or wires, etc.)
  • Electronic devices (e.g., implanted cardiac defibrillator, cardiac pacemaker, deep brain/spinal cord or nerve stimulator, internal electrodes/wires, medication infusion devices, etc.)
  • History of metal working without proper eye protection, or injury with metal shrapnel or metal slivers
  • Claustrophobia
  • Pregnancy
  • Predisposition to seizures (e.g., personal history of seizures, family history of seizures epilepsy, pregnancy, alcoholism, etc.)
  • Use of medications that increase the likelihood of seizures (e.g., bupropion SR, citalopram, duloxetine, ketamine, gamma-hydroxybutyrate, etc.)
  • History of surgical procedures performed on the brain or spinal cord
  • History of severe head trauma followed by loss of consciousness
  • History of fainting spells or syncope
  • Hearing problems or tinnitus

Study Design

Enrollment

120 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: TMS targeting OFC anterior networks

Participants will receive TMS and sham targeting the OFC network.

experimental: Experimental: TMS targeting posterior OFC networks

Participants will receive TMS and sham targeting the posterior OFC network.

Interventions

Real transcranial magnetic stimulation (TMS) before conditioning

Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the conditioning phase of the task.

Real transcranial magnetic stimulation (TMS) before devaluation test

Real TMS will be applied using the MagVenture MagPro X100 stimulator with the active side of the Cool-B65 A/P coil before the devaluation test phase of the task.

Sham transcranial magnetic stimulation (TMS)

Sham TMS will be applied using the MagVenture MagPro X100 stimulator with the placebo side of the Cool-B65 A/P coil.

Primary outcome measure

  • Behavior on devaluation task [ Time Frame: 1 hour after intervention ]
  • Resting-state functional magnetic resonance imaging [ Time Frame: 1 hour after intervention ]

Central Contacts and Locations

Central contacts

Christina Zelano, PhD

312-503-4437c-zelano@northwestern.edu

Greg Lane, PhD

312-503-7244

Locations

Northwestern University

Recruiting

Chicago, Illinois, United States, 60657

Contacts

Daria Porter, PhD

312-503-4223daria.porter@northwestern.edu

Principal Investigator:

Christina Zelano, PhD

More Information

Sponsor

Northwestern University

Last update posted

Aug 19, 2024

Last verified

Aug, 2024

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Northwestern University on 2024-08-19.